14-3-3 proteins are involved in several cellular processes, including the G1/S and G2/M cell cycle transitions. However, their roles during mitosis are not well understood. Here, we showed that depletion of 14-3-3Z, a 14-3-3 protein isoform, enhanced mitotic cell death, resulting in sensitization to microtubule inhibitors and inhibition of aneuploidy formation. The enhanced mitotic cell death by depletion of 14-3-3Z appeared to be both caspase-dependent and independent. Furthermore, enhanced mitotic cell death and a reduction in aneuploidy following 14-3-3Z depletion were independent of the mitotic checkpoint, which is thought to be the primary signaling event in the regulation of the cell death induced by microtubule inhibitors. When 14-3-3Z depletion was combined with microtubule inhibitors in HCT116 and U87MG cells, it sensitized both cancer cell lines to microtubule inhibitors. These results collectively suggest that 14-3-3Z may be required for mitotic progression and may be considered as a novel anti-cancer strategy in combination with microtubule inhibitors.
INTRODUCTION
14-3-3 proteins, which have been found in all eukaryotic organisms studied so far, are a family of highly homologous proteins comprising seven mammalian isoforms (b, g, Z, t, s, e and x). These proteins have crucial roles in a wide variety of cellular processes, such as cell cycle progression, the DNA damage checkpoint and apoptosis. 14-3-3 proteins act by binding to the phosphorylated consensus motifs of their target proteins and regulating their interactions, subcellular localization and enzymatic activities. In particular, the regulatory roles of 14-3-3 proteins in the G1/S and G2/M transitions have been studied extensively, and the proteins have been shown to inhibit premature entry into S phase and mitosis. [1] [2] [3] However, our understanding of the roles of 14-3-3 proteins during mitosis is limited, despite recent reports showing their involvement in cytokinesis. 4 ,5 As 14-3-3 proteins bind to many target proteins during mitosis, and some interactions are mitosis-specific, it might be reasonable to assume that they have multiple roles during the progression of mitosis. 5, 6 The mitotic checkpoint, also known as the spindle assembly checkpoint, ensures accurate chromosome segregation during mitosis by delaying the onset of anaphase until all kinetochores are properly attached to the microtubules and are under tension. 7 Microtubule inhibitors disrupt mitotic progression and activate the mitotic checkpoint resulting in mitotic arrest. This arrest can be prolonged and cause cell death unless the mitotic checkpoint, which is thought to be a major factor in the cytotoxicity of microtubule inhibitors, is satisfied. 8 However, as is characteristic for all checkpoints, some cells exit mitotic arrest even without satisfying the mitotic checkpoint in a process called adaptation or slippage and survive in aneuploidy, which increases with the presence of mitotic checkpoint defects and can also promote tumorigenesis. [9] [10] [11] [12] [13] [14] [15] Thus, factors influencing mitotic checkpoint adaptation or slippage and the fate of cells after adaptation or slippage should be investigated to better understand the links between the mitotic checkpoint and tumorigenesis.
In this study, we investigated the possible roles of 14-3-3 proteins in mitosis and showed that depletion of 14-3-3Z, but not 14-3-3b or s, enhanced mitotic cell death, which, in turn, sensitized cells to microtubule inhibitors. Furthermore, enhanced mitotic cell death by depleting 14-3-3Z reduced aneuploidy formation upon treatment with microtubule inhibitors even when the mitotic checkpoint was inactivated. These results suggest that 14-3-3Z may have important roles during mitotic progression and aneuploidy formation. We also investigated the possibility of using combinational treatment of 14-3-3Z depletion with microtubule inhibitors as a cancer therapeutic strategy. Depletion of 14-3-3Z in HCT116, a human colon cancer cell line and U87MG, a human glioblastoma cell line, significantly sensitized mitotic cell death induced by microtubule inhibitors.
RESULTS
Depletion of 14-3-3Z enhances mitotic cell death To elucidate how the 14-3-3 isoforms are involved in mitosis, HeLa cells were transfected with control luciferase short hairpin RNA (shRNA) (shLuc), shRNA targeting 14-3-3b, Z, or s and then subjected to western blotting, time-lapse photography and fluorescence-activated cell sorting (FACS) analyses. Western blot analyses verified the depletion efficacy of each shRNA and the absence of cross-isoform depletion (Figure 1a ). Depleting the isoforms did not cause significant changes in the expression level of the 14-3-3 family of proteins (14-3-3 all isoforms). Interestingly, the depletion of 14-3-3Z markedly induced mitotic cell death (Figures 1b and c) . Approximately 30% of the 14-3-3Z-depleted cells died during mitosis, which was significantly higher than that of the control or other isoform-depleted cells. This may not due to off-target effects because shRNAs to two different regions of the 14-3-3Z gene showed similar results. These results suggest that 14-3-3Z may be required for mitotic progression.
The time-lapse results were further analyzed to elucidate the possible causes of mitotic cell death in 14-3-3Z-depleted cells. Compared with the chromosomes in the shLuc-transfected control cells, which were properly condensed and segregated during mitotic progression, those in the 14-3-3Z-depleted cells were less condensed and not segregated properly. These cells ultimately died, which was identified by simultaneous membrane blebbing and contraction with chromosome shrinkage (Figure 1c ), indicating that 14-3-3Z-depletion caused defects in chromosome segregation during mitosis, which may have enhanced mitotic cell death.
Depletion of 14-3-3Z sensitizes cells to microtubule inhibitors The balance between survival and death signaling during mitosis may be an important factor determining sensitivity to microtubule inhibitors during cancer therapy and the generation of aneuploids leading to tumorigenesis. [16] [17] [18] As depleting 14-3-3Z enhanced cell death during mitosis, it should increase sensitivity to microtubule inhibitors but decrease the generation of aneuploid cells in response to mitotic failure. To test this idea, HeLa cells were transfected with either shLuc or sh14-3-3Z and then treated with nocodazole, a microtubule inhibitor. Some of the shLuctransfected cells initially arrested at mitosis upon nocodazole treatment eventually died (Figures 2a and b, R4-gated population) , and the others exited the arrest in a process called mitotic adaptation or slippage and then became aneuploid (Figures 2a  and b, 44N of R3-gated population). 9, 13, 19 The chromosome status of some of the R4-gated population was o2N and that of the other population was between 2N and 4N (marked by arrow), which may have been degraded after being arrested at 4N by the nocodazole treatment. sh14-3-3Z-transfected cells were also arrested during mitosis but more cells died instead of becoming aneuploid (44N). Cell death was determined based on cell morphology and DNA content (Figures 2a and b) . (Figure 2d ). Thus, the enhanced mitotic cell death caused by 14-3-3Z depletion resulted in sensitization and reduction in the aneuploid population after microtubule inhibitor treatment.
Prevention of aneuploidy formation by 14-3-3Z depletion is not dependent on the mitotic checkpoint In many cases, cell death during mitotic arrest and preventing aneuploidy are dependent on the mitotic checkpoint. 20 To determine if the mitotic checkpoint is involved in the sensitization to microtubule inhibitors and the reduction of aneuploidy by 14-3-3Z depletion, HeLa cells were transfected with shLuc or sh14-3-3Z in combination with shRNA targeting BubR1 or Mad2, which are key mitotic checkpoint regulators (Figure 3b ). Inactivating the mitotic checkpoint significantly increased the aneuploid population in shLuc-transfected cells upon nocodazole treatment (Figure 3a , 12.6% in shLuc vs 48.8% in shBubR1 þ shLuc and 43.0% in shMad2 þ shLuc). However, depletion of 14-3-3Z significantly reduced the aneuploid populations of mitotic checkpoint-inactivated cells, which were similar to those of the mitotic checkpoint-active control cells upon nocodazole treatment (Figure 3a , 3.9% in sh14-3-3Z vs 4.6% in shBubR1 þ sh14-3-3Z and 5.9% in shMad2 þ sh14-3-3Z). In contrast, cell death upon nocodazole treatment increased with 14-3-3Z depletion (Supplementary Figure S1 , R1: dead or dying cell population, R2: live-cell population). A similar result was obtained using another shRNA targeting a different region of the 14-3-3Z gene (sh14-3-3Z 616), indicating that the phenotypes produced by depleting 14-3-3Z may not be off-target effects (Supplementary Figure S2) . Enhanced cell death was further verified by the expression profiles of cell death-related proteins, namely apoptosis-inducing factor (AIF), caspase-3 and caspase-9 ( Figure 3c ). 21, 22 The expression levels of AIF, an effector of caspase-independent cell death, were similar between the control and 14-3-3Z-depleted cells before nocodazole treatment. However, the AIF levels in the 14-3-3Z-depleted cells were much higher than those in the control cells 36 h after nocodazole treatment. In parallel, the levels of active, cleaved caspase-3 and -9 in the 14-3-3Z-depleted cells were higher compared with those in the control cells upon nocodazole treatment. We next investigated how depleting the 14-3-3 b or s isoforms affected mitotic cell death and aneuploidy formation following nocodazole treatment when the mitotic checkpoint was inactivated. Each 14-3-3 isoform was depleted simultaneously with BubR1, treated with nocodazole for 36 h, and then subjected to FACS analysis. The aneuploid population in the 14-3-3b-depleted cells was smaller than that in the shLuc-transfected control cells but larger than that in the 14-3-3Z-depleted cells, implying an inverse correlation between the formation of an aneuploid population and mitotic cell death (Figures 1b and 3) . However, in the 14-3-3s-depleted cells, where mitotic cell death was similar to that of shLuc-transfected control cells, the aneuploid population was larger than that in the shLuc-transfected control cells (Figures 1b and 3d ). This result may be due to the regulatory roles of 14-3-3s during mitotic exit and aneuploidy formation. 5 Simultaneous inactivation of the mitotic checkpoint and the regulatory roles of 14-3-3s during mitotic exit may result in 14-3-3Z depletion sensitizes cancer cells to nocodazole CG Lee et al enhanced aneuploidy formation. Taken together, these results suggest that depleting 14-3-3Z, but not 14-3-3b or s, enhanced mitotic cell death, resulting in a sensitization to microtubule inhibitors and preventing aneuploidy formation, even in cells with defects at the mitotic checkpoint.
Enhanced cell death and preventing aneuploidy formation by 14-3-3Z depletion may occur in both caspase-dependent and independent manners As both AIF and caspases were activated in 14-3-3Z-depleted cells following nocodazole treatment, the enhanced cell death and formation of reduced aneuploids following 14-3-3Z depletion may occur in both caspase-dependent and independent manners. Consistent with these results, ectopic expression of Bcl2 or Z-VAD-FMK, a pan-caspase inhibitor, did not completely block the cell death caused by 14-3-3Z depletion upon nocodazole treatment in the colony outgrowth assays (Supplementary Figure S3) . The caspase pathway dependency on the aneuploidy formation was further investigated. When BubR1 or Mad2 was depleted simultaneously with 14-3-3Z, Z-VAD-FMK did not block the inhibitory effect of 14-3-3Z depletion on aneuploidy formation (Figures 4a and b) . This result may not have been owing to the inability of Z-VAD-FMK to block the caspase pathway, as it retarded the cell death progression of the 14-3-3Z þ BubR1, or Mad2-depleted cells. As the decision to live or die may occur at a step (s) upstream of the caspases, we investigated whether ectopic expression of Bcl2, a well-known upstream inhibitor of the caspase pathway, can recover aneuploidy formation in 14-3-3Z-depleted cells. 23 Ectopic expression of Bcl2 produced similar results as the Z-VAD-FMK treatment (Figure 4c ). The reduced formation of aneuploids following 14-3-3Z depletion could not be recovered by ectopic expression of Bcl2 when BubR1 was depleted. These results suggest that 14-3-3Z depletion may result in the activation of multiple cell-death signaling pathways, leading to enhanced mitotic cell death.
The phenotypes following depletion of 14-3-3Z were not because of mitotic catastrophe by defects in the G2/M checkpoint nor caspase-independent mitotic death (CIMD) by downregulation of Bub1 As depletion of 14-3-3Z increased mitotic cell death, it may sensitize cells specifically to drugs targeting mitotic events. shLuctransfected control and 14-3-3Z-depleted cells were treated with several cancer drugs, and cell death was analyzed by Annexin V and propidium iodide (PI) staining. As expected, the differences in sensitivity between the control cells and the 14-3-3Z-depleted cells were larger for the drugs targeting mitosis, such as taxol and vincristine, than doxorubicin and hydroxyurea (Figure 5a ). Similar results were obtained with other well-known cancer drugs, such as cisplatin and rapamycin (Supplementary Figure S4) . These results suggest that a combination of 14-3-3Z depletion and microtubule inhibitors may enhance the therapeutic effect of microtubule inhibitors and be a good candidate for the development of new cancer therapies.
14-3-3 proteins have important roles in the G2/M checkpoint. 24 If the G2/M checkpoint is defective, cells with DNA damage proceed into mitosis and die of mitotic catastrophe. 25 Thus, we examined whether 14-3-3Z depletion might cause defects in the G2/M checkpoint, resulting in enhanced mitotic cell death. HeLa cells transfected with a control luciferase or 14-3-3Z shRNA were treated with etoposide (VP-16), a compound that activates the G2/M checkpoint by inducing DNA damage, and then released into the culture media containing nocodazole, to trap cells in mitosis, and then analyzed by FACS using phospho-MPM2 (a mitotic marker) and PI staining (Figures 5b and c) . This mitotic trap tests whether the G2/M checkpoint is stringent or not. 26 As shown in Figure 5c , treatment with 50 mM VP-16 arrested the cells and their entry into mitosis possibly due to activation of the G2/M checkpoint in both the control and 14-3-3Z-depleted cells and no significant differences in the percentage of mitotic cells were observed (R1 population). Furthermore, the mitotic population of asynchronized cells and cells treated with a lower concentration of VP-16 were similar between the control and 14-3-3Z-depleted cells. This observation indicates that 14-3-3Z depletion does not cause significant defects in the G2/M checkpoint, and that enhanced mitotic cell death in 14-3-3Z-depleted cells may not result from defects in the G2/M checkpoint.
One of well-identified mitotic cell deaths is CIMD, which occurs because of partial depletion of Bub1 (or reduced level of Bub1 expression). CIMD is independent on caspase activation but dependent on p73 and AIF. 27 To investigate whether CIMD may be involved in the cell death by 14-3-3Z depletion, we have examined Bub1 expression in the 14-3-3Z-depleted cells. Depletion of 14-3-3Z by shRNAs slightly increased Bub1 expression. Bub3 expression was not significantly changed by 14-3-3Z depletion (Figure 5d ). Taken together, these results suggest that the cell death by 14-3-3Z depletion may not be because of mitotic catastrophe by defects in the G2/M checkpoint or CIMD induced by partial depletion of Bub1.
14-3-3Z depletion sensitized cancer cells to microtubule inhibitors As 14-3-3Z depletion sensitized HeLa cells to microtubule inhibitors, we further investigated whether 14-3-3Z depletion can be applied to other cancer cells. HCT116, a colon cancer cell line and U87MG, a glioblastoma cell line were used for this analysis. 14-3-3Z was depleted using shRNAs and then treated with nocodazole (Figures 6a and b) . Both cell lines were relatively resistant to nocodazole treatment alone at the conditions tested. However, 14-3-3Z depletion significantly sensitized both cell lines to nocodazole treatment.
Recently, it was reported that 14-3-3Z expression is detectable specifically in astrocytoma tissues and glioblastoma cell lines, and that the levels were well correlated with astrocytoma malignancy grade. 28 Thus, it may be reasonable to further develop 14-3-3Z depletion as a combination therapy with microtubule inhibitors for astrocytoma/glioblastoma. As vincristine is included in the current chemotherapy for astrocytoma, we combined 14-3-3Z depletion with vincristine instead of nocodazole, which is not approved for cancer therapy. In consistent with the results using nocodazole, 14-3-3Z depletion sensitized U87MG to vincristine, which was determined using two different assays (Figures 7a and  b) . Taken together, these results suggest that 14-3-3Z may be a potential therapeutic target for cancer, especially astrocytoma/ glioblastoma.
DISCUSSION
Several types of mitotic cell death, such as mitotic catastrophe, CIMD and mitotic cell death by chromosome fragmentation, have been reported so far. Mitotic catastrophe is a well-known type of mitotic cell death that occurs when cells with DNA damage enter mitosis because of the impaired G2/M checkpoint. 25 The induction of mitotic catastrophe is useful for cancer therapies using DNAdamaging agents and known to be dependent on the mitotic checkpoint. 20 CIMD was observed when Bub1 was partially depleted and depended on p73, AIF and endonuclease G but not on the caspase pathway or p53. 27 CIMD is supposed to protect cells from aneuploidy and tumorigenesis. Mitotic cell death by 14-3-3Z depletion is quite different from mitotic catastrophe and CIMD, as it is not dependent on the mitotic checkpoint and occurs even in the absence of defects in the G2/M checkpoint. 14-3-3Z depletion enhances mitotic cell death without partial depletion of Bub1, which is necessary for CIMD (Figure 5d ). Mitotic cell death by 14-3-3Z depletion is also different from mitotic cell death by shBubR1 shBubR1 + sh14-3-3 η 14-3-3Z depletion sensitizes cancer cells to nocodazole CG Lee et al chromosome fragmentation in terms of caspase dependency, which is possibly induced by genomic instability or environmental insults. 29 However, several mitotic cell deaths have been recently identified but have not been compared side by side. Further studies may be needed to identify the relevance and difference among several mitotic cell deaths.
Asyn
In the time-lapse analysis, the chromosomes in the 14-3-3Z-depleted cells did not appear to be segregated completely during mitotic progression (Figure 1c) . As proper chromosome segregation is necessary for maintaining chromosome integrity, defects can be a cause of mitotic cell death. This may explain why 14-3-3Z-depleted cells are more sensitive to microtubule inhibitors than other cancer drugs. The defects in chromosome segregation caused by 14-3-3Z depletion may be augmented by microtubule inhibitors. Maintenance of chromosome integrity is regulated by the mitotic checkpoint during mitosis and the postmitotic checkpoint at the G1 phase. 30, 31 Cells that cannot satisfy the checkpoints are arrested, resulting in cell death or The cells were treated with VP-16 (10 or 50 mM) for 1 h, 36 h after the transfection, and then released into media containing nocodazole for 18 h. 26 The cells were stained with antiphospho-MPM2 (a mitotic marker), allophycocyanin-labeled secondary antibodies and PI, and then subjected to flow cytometry analysis. Representative results are shown. (d) The cells were treated with nocodazole 36 h after the transfection, harvested at the indicated time points and subjected to western blot analyses with the indicated antibodies.
tumorigenesis. Information on the roles of 14-3-3 proteins in mitotic progression and the mitotic and the postmitotic checkpoints is very limited, except for the roles of 14-3-3b and s during cytokinesis, which interact with PKCe and eukaryotic translation initiation factor 4B, respectively. 4, 5 As mitosis-specific interactions between the 14-3-3 family and target proteins have been reported, it is highly possible that the 14-3-3 family proteins have multiple roles during mitotic progression. 5, 6 In our preliminary results, 14-3-3Z was strongly phosphorylated in the in vitro kinase assay by Plk1, a well-known mitotic kinase that has multiple roles during mitotic progression. Further studies may be needed to identify the molecular targets of 14-3-3Z during mitosis, the possibility of in vivo phosphorylation and the regulation of 14-3-3Z by Plk1.
The sensitization of cells to microtubule inhibitors and the inhibition of aneuploidy formation in mitotic checkpoint-inactivated cells by 14-3-3Z depletion was not completely blocked by either Z-VAD-FMK, a pan-caspase inhibitor, or ectopic expression of Bcl2, a well-known upstream inhibitor of the caspase pathway. The mechanisms involved in the phenotypes appear to be complicated. Depletion of 14-3-3Z increased the expression of cell deathrelated molecules, such as caspase-9 and Bim (Figure 3c and data not shown). Although information on the relationship between the 14-3-3 family and caspase-9 is very limited, the interaction between the 14-3-3 family and Foxo3a, a transcription regulator of Bim expression, is very well known. 32, 33 Akt phosphorylates Foxo3a, and the phosphorylated form is sequestrated by 14-3-3 proteins. In that way, expression of Bim, a proapoptotic BH3-ony protein, is inhibited. Thus, Foxo3a is a possible molecular target of 14-3-3Z for regulating mitotic progression. Caspase-9 is also phosphorylated by Akt, but regulation by 14-3-3 proteins is unknown. 32 However, caspase-9 is still a possible target of 14-3-3Z-mediated regulation. Furthermore, molecules involved in the survival/death signaling pathway other than Foxo3a and caspase-9, as well as chromosome segregation are targets of 14-3-3Z. It would be interesting and valuable to investigate which molecules 14-3-3Z-mediated regulation targets.
Astrocytoma, including glioblastoma, the most malignant type of astrocytoma, is a malignant primary brain tumor that carries a poor prognosis and is relatively resistant to conventional therapies. Thus, it is essential to develop more effective therapeutic methods to treat such types of cancers. Considering the specific expression of 14-3-3Z and correlation of its expression level with astrocytoma malignancy, 14-3-3Z may be a possible Figure 6 . 14-3-3Z depletion sensitized HCT116 (colon cancer cell line) and U87MG (glioblastoma cell line) to nocodazole. HCT116 (a) and U87MG (b) cells were transfected with the indicated shRNAs, and dead cells were removed by washing 24 h later and then cultured with puromycin (0.3 ug/ml) for 3 days. After puromycin selection, the cells were treated with nocodazole for another 36 (HCT116) or 72 h (U87MG), fixed in 70% ethanol, stained with PI, and analyzed by flow cytometry to determine DNA content. Sub-G1 and aneuploid populations (44N) are indicated, and their percentages are shown. therapeutic target for astrocytoma. As 14-3-3Z depletion can sensitize U87MG, a glioblastoma cell line, to vincristine, it is worthwhile to further develop the combination of 14-3-3Z depletion with microtubule inhibitors as a therapeutic strategy for astrocytoma.
MATERIALS AND METHODS
Plasmid construction, cell culture and transfection Sense and antisense oligonucleotides for the shRNAs targeting human 14-3-3b (5
, and Mad2 (5 0 -GGAA GAGUCGGGACCACAG-3 0 ) were generated, annealed and cloned into the pSuper.puro vector, according to the manufacturer's instructions (Oligoengine, Seattle, WA, USA). 5, 34 HeLa and U87MG cells were purchased from the American Type Culture Collection (Manassas, VA, USA) and HCT116 cells were kindly provided by Bert Vogelstein (Baltimore, MD, USA). Cell culture and transfections were performed as described previously. 35 Flow cytometry analysis Cells were harvested at various time points, fixed in 70% ethanol and stained with 40 mg/ml PI in the presence of 50 mg/ml RNase A. The DNA content of 10 000 cells under each condition was analyzed on a Becton Dickinson FACScan cytometer or FACS Aria (Franklin Lakes, NJ, USA) using CellQuest or FACSDiva software (BD Biosciences, San Jose, CA, USA). To calculate the mitotic index, cells fixed in 70% ethanol were incubated on ice with anti-phospho-MPM2 (Upstate, Temecula, CA, USA) for 1 h, followed by a 1-h incubation with allophycocyanin-labeled secondary antibody before PI staining. Cell death was measured using the Annexin V-FITC Apoptosis Detection kit (BD Pharmingen, San Diego, CA, USA), according to the manufacturer's instructions.
Live-cell imaging analysis
To estimate the frequency of cell death during mitosis, cells were transfected with a plasmid encoding H2B-RFP (to visualize the chromosomes) and a plasmid carrying a shRNA targeting each 14-3-3 protein isoform, and further cultured in DT 0.15-mm dishes for 36 h. Images were acquired every 3 min with a 30-ms exposure for 36 h using a Â 40 NA 0.75 objective on an Axiovert 200M microscope containing a Zeiss AxioCam HRm (Carl Zeiss, Oberkochen, Germany).
Western blot analysis
Protein samples were separated on an SDS-PAGE gel, transferred to a nitrocellulose filter, blocked and analyzed with anti-14-3-3b, Bcl2, Mad2, PARP (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 14-3-3s, (Millipore, Temecular, CA, USA), AIF, caspase-3, caspase-9 (Cell Signaling Technology, Danvers, MA, USA), 14-3-3Z (Serotec, Oxford, UK), Bub1, Bub3, BubR1 (BD Pharmingen), g-H2AX (Phospho S139) (Abcam, Cambridge, MA, USA) and actin (Sigma, St Louis, MO, USA) antibodies. 
